3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
3
Terminated
2
Withdrawn
1
Unknown
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Ovarian Neoplasms
9
Neoplasms
3
Endometrial Neoplasms
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Head and Neck Neoplasms
2
Esophageal Neoplasms
2
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Thrombocytopenia
1
Stomach Neoplasms
1
Solid Tumor, Adult
1
Recurrence
1
Rectal Neoplasms
1
Osteosarcoma
1
Oligodendroglioma
1
Neutropenia
1
Neuroblastoma
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Glioma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Cystadenocarcinoma, Serous
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Biliary Tract Neoplasms
1
Astrocytoma
1
Interventions
Gemcitabine
100
130-nm albumin-bound paclitaxel
34
Oxaliplatin
28
Capecitabine
27
Fluorouracil
25
Albumin-Bound Paclitaxel
23
Leucovorin
19
Irinotecan
18
Erlotinib Hydrochloride
14
Cyclophosphamide
12
Radiosurgery
11
pembrolizumab
10
Radiotherapy
10
Nivolumab
10
Bevacizumab
10
Surgical Procedures, Operative
9
avelumab
7
Docetaxel
7
Taxes
6
Cisplatin
6
ruxolitinib
5
folfirinox
5
Specimen Handling
5
Paclitaxel
5
Everolimus
5
Cetuximab
5
ALT-803
5
trametinib
4
spartalizumab
4
fludarabine
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Pancreatic Neoplasms
×
niraparib
×
Clear all
NCT05442749
2026-02-17
PARPi-PANC
Centre Leon Berard
Phase 2
Terminated
2 enrolled
NCT05169437
2025-10-29
PAVO
Tempus AI
Phase 2
Terminated
22 enrolled
17 charts